SLRX Salarius Pharmaceuticals Inc: Net Margin

Salarius (SLRX) - corporate logo

Salarius Pharmaceuticals (SLRX) is recruiting leading oncologists to develop protein-protein interaction inhibitors. The business capitalization relies on grants and the future sale of targeted cancer therapy drugs. This chart from the GURU.Markets terminal shows that the integral net margin indicator demonstrates profit efficiency, with the value 0.00 capturing the metric level. The company's growth trajectory depends exclusively on the results of clinical trials.

salariuspharma.com (SLRX) - Company Sales Margin from 07/04/2022 to 01/08/2026

Summary analytical data breakdowns for Salarius Pharmaceuticals (SLRX)

Summary company analytics:Salarius Pharmaceuticals
Manufactured product of Salarius Pharma

Salarius Pharmaceuticals (SLRX) is developing unique epigenetic drugs for pediatric oncology and is currently in the early stages of clinical trials. The absence of commercial sales makes net profit calculations dependent on operating expenses, which directly impacts final profitability. This metric measures the profit margin of every dollar of revenue, separating real efficiency from speculative volatility. Analyzing the net profit margin allows for the timely identification of asset overvaluation. An investor can assess business sustainability using this chart.

Competing companies

ONC: Net Sales Margin|Net Margin Halozyme Inc. (HALO)|Net Margin RevMed|Net Return on Sales AAPG (Ascentage Pharma Group)|Net Sales Margin CGON|UroGen Pharma - Net Return on Sales|Bicara Therapeutics - Return on Sales by Net Profit|Net Sales Margin Personalis Inc PSNL|Erasca Oncology - Net Sales Margin|Net Profit Rate DCTH (Delcath Corp)|YMAB: Net Sales Margin|AURA - Company Sales Margin|CADL (Candel Therapeutics Inc.) - Net Sales Margin|Net Return on Sales ARAY (Accuray)|Return on Sales by Net Profit SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Net Margin|Net Margin Citius Oncology, Inc. CTOR|HURA - Return on Sales by Net Profit|protaratx.com - Net Sales Margin|FATE - Net Sales Margin|WHWK: Net Sales Margin|TScan Therapeutics (TCRX) - Net Sales Margin|Net Margin Champions Oncology|Net Margin XBIT|Net Sales Margin CVM|Return on Sales by Net Profit OS Therapies Inc. OSTX|Net Margin Radiopharm Theranostics Limited RADX|artivabio.com (ARTV) - Net Margin|ANL - Net Margin|Net Margin verupharma.com|TPST: Net Sales Margin|XLO - Company Sales Margin|Net Margin Renovaro|Net Sales Margin muraloncology.com|Net Sales Margin KAPA|Company Sales Margin OnKure Therapeutics, Inc.|Net Sales Margin GDTC (w2.cytomed.sg)|CRIS - Return on Sales by Net Profit|Apollomics - Net Sales Margin|Tharimmune Corp (THAR) - Return on Sales by Net Profit|ADVB: Net Sales Margin|Return on Sales by Net Profit Genprex|CLDI (Calidi Biotherapeutics, Inc.) - Net Sales Margin|Net Return on Sales SBFM (Sunshine Biopharma)|Net Margin Xenetic Bio (XBIO)|Return on Sales by Net Profit Purple Biotech PPBT|Net Margin American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Net Margin|Checkpoint Therapeutics Inc. - Net Sales Margin|Net Profit Rate ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Return on Sales by Net Profit|Ikena Oncology, Inc. - Net Profit Rate|Return on Sales by Net Profit NTBL|VIRX: Net Profit Rate|Net Margin MorphoSys Corporation (MOR)|NAYA - Net Margin|Net Sales Margin AAPGV (Ascentage)